CMA refers UnitedHealth acquisition to Phase II

The UK’s antitrust enforcer has rejected a divestiture package from UnitedHealth and opened an in-depth probe to determine if the US healthcare giant’s £1.2 billion acquisition of EMIS Group could restrict competition for supplying vital software to the country’s national health service.

Unlock unlimited access to all Global Competition Review content